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BACKGROUND
Several studies have compared the treatment effects of coronary stenting and coro-
nary-artery bypass grafting (CABG). However, there are limited data regarding the 
long-term outcomes of these two interventions for patients with unprotected left 
main coronary artery disease.
METHODS
We evaluated 1102 patients with unprotected left main coronary artery disease who 
underwent stent implantation and 1138 patients who underwent CABG in Korea be-
tween January 2000 and June 2006. We compared adverse outcomes (death; a com-
posite outcome of death, Q-wave myocardial infarction, or stroke; and target-vessel 
revascularization) with the use of propensity-score matching in the overall cohort 
and in separate subgroups according to type of stent.
RESULTS
In the overall matched cohort, there was no significant difference between the stent-
ing and CABG groups in the risk of death (hazard ratio for the stenting group, 1.18; 
95% confidence interval [CI], 0.77 to 1.80) or the risk of the composite outcome (haz-
ard ratio for the stenting group, 1.10; 95% CI, 0.75 to 1.62). The rates of target-vessel 
revascularization were significantly higher in the group that received stents than in 
the group that underwent CABG (hazard ratio, 4.76; 95% CI, 2.80 to 8.11). Compari-
sons of the group that received bare-metal stents with the group that underwent 
CABG and of the group that received drug-eluting stents with the group that under-
went CABG produced similar results, although there was a trend toward higher rates 
of death and the composite end point in the group that received drug-eluting stents.
CONCLUSIONS
In a cohort of patients with unprotected left main coronary artery disease, we found 
no significant difference in rates of death or of the composite end point of death, 
Q-wave myocardial infarction, or stroke between patients receiving stents and those 
undergoing CABG. However, stenting, even with drug-eluting stents, was associated 
with higher rates of target-vessel revascularization than was CABG.
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Significant narrowing of the left main coronary artery puts a patient at high risk, since it can jeopardize the entire myo-
cardium of the left ventricle, and it has the worst 
prognosis of any form of coronary artery dis-
ease.1 On the basis of clinical trials that show a 
survival benefit with bypass surgery as compared 
with medical treatment,1-4 coronary-artery bypass 
grafting (CABG) has been considered standard 
therapy for patients with left main coronary artery 
disease and is recommended by current practice 
guidelines.5,6 Because of concern about procedural 
risk and long-term durability, percutaneous coro-
nary intervention (PCI) usually has been restricted 
to patients who are poor candidates for surgery 
or have left main coronary artery disease that is 
“protected” by a patent bypass graft to the left an-
terior descending or circumflex artery.
The development of coronary-artery stenting 
has led to a reevaluation of the role of PCI for left 
main coronary artery disease, and several studies 
have reported on the midterm safety and feasi-
bility of stenting.7-9 Interest in stenting of the left 
main coronary artery has increased further with 
the availability of drug-eluting stents that signifi-
cantly reduce the rates of restenosis and repeat 
revascularization.10-12 However, there are limited 
data on the long-term safety and effectiveness of 
PCI with bare-metal or drug-eluting stents, as 
compared with CABG, in patients with unprotect-
ed left main coronary artery disease. We therefore 
compared the long-term outcomes of the implan-
tation of coronary stents and CABG among pa-
tients with unprotected left main coronary artery 
disease in Korea, where stenting of the left main 
coronary artery has been a more common prac-
tice than in Western countries, as recorded in the 
MAIN-COMPARE (Revascularization for Unpro-
tected Left Main Coronary Artery Stenosis: Com-
parison of Percutaneous Coronary Angioplasty 
versus Surgical Revascularization) registry.
Me thods
Study Population
The MAIN-COMPARE registry holds data on con-
secutive patients from 12 major cardiac centers 
in Korea that performed PCI or CABG for unpro-
tected left main coronary artery disease (defined 
as stenosis of more than 50%) between January 
2000 and June 2006. We excluded patients who 
had undergone previous CABG, those who under-
went concomitant valvular or aortic surgery, and 
those who had myocardial infarction with ST-seg-
ment elevation or presented with cardiogenic 
shock. The registry is sponsored by the Korean 
Society of Interventional Cardiology. There was 
no industry involvement in the design, conduct, 
or analysis of the study. The local ethics commit-
tee at each hospital approved the use of clinical 
data for this study, and all patients provided writ-
ten informed consent.
Patients underwent PCI, instead of CABG, be-
cause of either the patient’s or physician’s prefer-
ence or the high risk associated with CABG (see 
the Supplementary Appendix, available with the 
full text of this article at www.nejm.org). From 
January 2000 through May 2003, coronary stent-
ing was performed exclusively with bare-metal 
stents, whereas from May 2003 through June 2006, 
exclusively drug-eluting stents were used. Methods 
of stent implantation for patients with left main 
coronary artery disease have been described pre-
viously10,13,14 (see the Supplementary Appendix). 
Interventions for other clinically important types 
of coronary artery disease were performed accord-
ing to current practice guidelines.6 All patients 
undergoing PCI were prescribed aspirin plus clopi-
dogrel (loading dose, 300 mg or 600 mg) or ti-
clopidine (loading dose, 500 mg) before or during 
the coronary intervention. After the procedure, 
aspirin was continued indefinitely. Patients treat-
ed with bare-metal stents were prescribed clopi-
dogrel or ticlopidine for at least 1 month, and pa-
tients treated with drug-eluting stents were 
prescribed clopidogrel for at least 6 months. Sur-
gical revascularization was performed with the use 
of standard bypass techniques.5 Whenever pos-
sible, the internal thoracic artery was used prefer-
entially for revascularization of the left anterior 
descending artery.
Follow-up and End Points
Clinical, angiographic, procedural or operative, 
and outcome data were collected with the use of 
a dedicated Internet-based reporting system. All 
outcomes of interest were confirmed by source 
documentation collected at each hospital and were 
centrally adjudicated by the local events committee 
at the University of Ulsan College of Medicine, 
Asan Medical Center, Seoul. For validation of com-
plete follow-up data, information about vital sta-
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Table 1. Baseline Characteristics of the Patients.*
Variable
Stent Group 
(N = 1102)
CABG Group 
(N = 1138) P Value
Demographic characteristics
Age (yr) <0.001
Median 62 64
Interquartile range 52–70 57–70
Male sex (%) 70.7 72.9 0.24
Cardiac or coexisting conditions 
Diabetes mellitus (% of patients)
Any diabetes 29.7 34.7 0.01
Insulin-dependent 6.8 8.2 0.22
Hypertension (% of patients) 49.5 49.4 0.94
Hyperlipidemia (% of patients) 28.5 32.6 0.04
Current smoker (% of patients) 25.6 29.8 0.03
Previous coronary angioplasty (% of patients) 18.1 11.0 <0.001
Previous myocardial infarction (% of patients) 8.1 11.6 0.005
Previous congestive heart failure (% of patients) 2.5 3.3 0.21
Chronic obstructive pulmonary disease (% of patients) 2.0 2.0 0.97
Cerebrovascular disease (% of patients) 7.1 7.3 0.84
Peripheral vascular disease (% of patients) 1.5 5.4 <0.001
Renal failure (% of patients) 2.7 3.0 0.71
Ejection fraction (%) <0.001
Median 62 60
Interquartile range 57–67 52–66
Electrocardiographic findings (% of patients) 0.53
Sinus rhythm 97.8 97.1
Atrial fibrillation 2.0 2.7
Other 0.2 0.2
Clinical indication (% of patients) <0.001
Silent ischemia 3.0 2.2
Chronic stable angina 32.0 19.9
Unstable angina 55.2 68.1
Non–ST-elevation myocardial infarction 9.8 9.8
Angiographic characteristics
Involved location (% of patients) 0.04
Ostium, midshaft, or both 50.6 46.2
Distal bifurcation 49.4 53.8
Extent of diseased vessel (% of patients) <0.001
Left main only 25.2 6.2
Left main plus single-vessel disease 24.0 10.5
Left main plus double-vessel disease 26.0 26.3
Left main plus triple-vessel disease 24.8 57.0
Right coronary artery disease (% of patients) 35.9 70.7 <0.001
Restenotic lesion (% of patients) 2.9 1.2 0.005
* CABG denotes coronary-artery bypass grafting. Percentages may not total 100 because of rounding.
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tus was obtained through July 15, 2007, from the 
National Population Registry of the Korea Nation-
al Statistical Office with the use of a unique per-
sonal identification number.
Clinical follow-up after PCI and after CABG was 
recommended at 1 month, 6 months, and 1 year 
and then annually thereafter. Routine angiograph-
ic follow-up for all patients treated with PCI was 
recommended 6 to 10 months after the procedure. 
However, patients who were at high risk for pro-
cedural complications of angiography and had no 
symptoms or signs of ischemia, as well as patients 
who declined the recommendation, did not un-
dergo routine follow-up angiography. For patients 
who underwent CABG, angiographic follow-up 
was recommended only if there were ischemic 
symptoms or signs during follow-up.
The end points of the study were death; the 
composite of death, Q-wave myocardial infarc-
tion, or stroke; and target-vessel revascularization. 
All events were based on clinical diagnoses as-
signed by the patient’s physician and were cen-
trally adjudicated by an independent group of 
clinicians. Death was defined as death from any 
cause. Q-wave myocardial infarction was defined 
as documentation of a new abnormal Q wave af-
ter the index treatment. Stroke, as indicated by 
neurologic deficits, was confirmed by a neurolo-
gist on the basis of imaging studies. Target-vessel 
revascularization was defined as repeat revascu-
larization of the treated vessel, including any seg-
ments of the left anterior descending artery and 
the left circumflex artery.15
Statistical Analysis
Among patients who had unprotected left main 
coronary artery disease, we compared long-term 
outcomes for those who underwent PCI, irrespec-
tive of stent type, with the outcomes for those who 
underwent CABG. In addition, we compared the 
long-term outcomes of patients who received bare-
metal or drug-eluting stents with patients who un-
derwent CABG. Patients who received bare-metal 
stents were compared with patients who under-
went CABG between January 2000 and May 2003 
(Wave 1 of the registry). Patients who received 
drug-eluting stents were compared with patients 
who underwent CABG between May 2003 and June 
2006 (Wave 2 of the registry).
To reduce the effect of treatment-selection bias 
and potential confounding in this observational 
study, we performed rigorous adjustment for sig-I
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nificant differences in the baseline characteristics 
of patients with the use of propensity-score match-
ing.16,17 For each comparison (the entire cohort, 
Wave 1, and Wave 2), a separate propensity score 
for PCI versus CABG was derived. The details of 
the propensity-score method, with the resulting 
models and their predictive characteristics, are 
described in the Supplementary Appendix.
After all the propensity-score matches were 
performed, we compared the baseline covariates 
between the two intervention groups. Continuous 
variables were compared with the use of the 
paired t-test or the Wilcoxon signed-rank test, as 
appropriate, and categorical variables were com-
pared with the use of McNemar’s test. Statistical 
significance and the effect of treatment on out-
comes were estimated with the use of appropri-
ate statistical methods for matched data.18,19 In 
the propensity-score–matched cohort, the risks of 
each outcome were compared with the use of Cox 
regression models, with robust standard errors 
that accounted for the clustering of matched pairs. 
Survival curves were constructed with Kaplan–
Meier estimates and compared with the use of 
methods described by Klein and Moeschberger.19
All reported P values are two-sided, and P val-
ues of less than 0.05 were considered to indicate 
statistical significance. SAS software, version 9.1, 
and the R programming language were used for 
statistical analyses.
R esult s
Characteristics of the Study Population
Between January 2000 and June 2006, a total of 
2240 patients with unprotected left main coronary 
artery disease met the criteria for inclusion. Of 
these, 1102 were treated with PCI and 1138 with 
CABG. Of the patients who underwent PCI, 1073 
(97.4%) had clinical and angiographic conditions 
that made them eligible for either PCI or CABG, 
but they underwent PCI because of the patient’s 
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Figure 1. Kaplan–Meier Curves for Outcomes in a  
Cohort of Patients Matched for Propensity Scores Who 
Underwent Stent Implantation or Bypass Surgery.
Propensity matching for the entire cohort created 542 
matched pairs of patients. Panel A shows the outcomes 
for overall survival; Panel B, outcomes for freedom 
from death, Q-wave myocardial infarction, or stroke; 
and Panel C, outcomes for freedom from target-vessel 
revascularization. Event-free survival rates (at 1, 2, and 
3 years) were derived from paired Kaplan–Meier curves. 
CABG denotes coronary-artery bypass grafting.
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or physician’s preference. The remaining 29 pa-
tients (2.6%) had underlying conditions that made 
them poor candidates for surgery (8 were ≥80 
years of age and had a poor performance status, 
3 had limited life expectancy, 2 had a current ma-
lignant condition, 12 had a concomitant severe 
medical illness, and 4 had no suitable bypass 
conduits).
In the PCI group, 318 patients (28.9%) re-
ceived bare-metal stents and 784 (71.1%) received 
drug-eluting stents. Of the patients treated with 
drug-eluting stents, 607 (77.4%) received siroli-
mus-eluting stents and 177 (22.6%) received pac-
litaxel-eluting stents. The mean (±SD) number of 
stents implanted in a patient’s left main coro-
nary lesions was 1.2±0.5, the mean total length of 
the stents was 28.0±20.7 mm, and the mean stent 
diameter was 3.5±0.4 mm. The mean total num-
ber of stents implanted in a patient (including left 
main and other vessels) was 1.9±1.1.
In the CABG group, 478 patients (42.0%) un-
derwent off-pump surgery and 1120 (98.4%) re-
ceived at least one arterial conduit that, in 1096 
patients (97.9%), was used in revascularization of 
the left anterior descending artery. The mean num-
ber of grafts used was 2.9±1.0 (2.2±0.9 arterial 
grafts and 0.7±0.8 venous grafts).
The baseline characteristics of the study pa-
tients according to the revascularization proce-
dure are shown in Table 1. Patients undergoing 
CABG were significantly older and had a higher 
prevalence of diabetes, hyperlipidemia, smoking, 
and history of myocardial infarction or peripheral 
vascular disease than those receiving stents. Pa-
tients undergoing CABG were also more likely to 
have lower ejection fractions, to present with un-
stable angina, and to have distal-bifurcation ste-
nosis, three-vessel disease, and involvement of the 
right coronary artery. More patients in the PCI 
group than in the CABG group had undergone 
previous coronary angioplasty and had restenotic 
left main coronary lesions.
Follow-up
The median follow-up was 1017 days (interquartile 
range, 688 to 1451) in the PCI group and 1152 
days (interquartile range, 681 to 1590) in the CABG 
group. Complete follow-up data for major clinical 
events were obtained in 98.9% of the overall co-
hort. During follow-up, 187 patients (8.3%) died, 
of whom 127 (67.9%, or 5.7% of the overall co-
hort) died of a cardiovascular cause. Twenty pa-
tients (0.9%) had a Q-wave myocardial infarction, 
and 35 (1.6%) had a stroke. Target-vessel revascu-
larization was performed in 141 patients (6.3%).
Characteristics of Patients Matched  
for Propensity Scores
Details of the propensity-score analysis are pro-
vided in the Supplementary Appendix. After pro-
pensity-score matching was performed for the 
entire population, there were 542 matched pairs 
of patients (Table 2). In this matched cohort, 
25.5% of the PCI group received bare-metal stents 
and 74.5% received drug-eluting stents. After pro-
pensity-score matching was performed separately 
in the Wave 1 and Wave 2 cohorts, there were 207 
matched pairs of patients who received bare-metal 
stents and concurrent control patients who under-
went CABG, and 396 matched pairs of patients 
who received drug-eluting stents and concurrent 
control patients who underwent CABG. In the 
matched cohorts, there was no longer any signifi-
cant difference between the PCI group and the 
CABG group for any covariate, according to the 
use of statistical methods appropriate for matched 
data (Table 2).
Outcomes for the Matched Cohorts
Figure 1 and Table 3 show the long-term rates of 
clinical outcomes according to the treatment ap-
proach in the overall matched cohort. For the 542 
matched pairs, there was no significant differ-
ence between the PCI and CABG groups in the 
risk of death during the 3-year follow-up period. 
The rates of major adverse cardiovascular events 
(death, Q-wave myocardial infarction, or stroke) 
were also similar. However, the rate of target-ves-
sel revascularization was significantly higher in 
the PCI group than in the CABG group. Of the 
patients with initial PCI treatment who under-
went target-vessel revascularization during the 
study period, 82.1% underwent repeat PCI (stent-
ing or balloon angioplasty) and 17.9% underwent 
CABG. Of the patients with initial CABG treat-
ment who underwent target-vessel revasculariza-
tion, all underwent PCI, not repeat CABG. The 
risk of target-lesion revascularization specifically 
for restenosis of the left main coronary artery 
was also significantly higher in the PCI group 
than in the CABG group (hazard ratio, 2.72; 95% 
confidence interval [CI], 1.51 to 4.91).
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The rates of death at 3 years of follow-up did 
not differ significantly between the group that 
received bare-metal stents and the CABG group 
(Fig. 2 and Table 3). There was also no signifi-
cant difference between the two groups in the 
composite risk of death, Q-wave myocardial in-
farction, or stroke. However, the rate of target-
vessel revascularization was significantly lower 
among patients who underwent CABG than among 
those who received bare-metal stents. Of patients 
with bare-metal stents who underwent target-ves-
sel revascularization, 60.5% underwent repeat PCI 
and 39.5% underwent CABG. All patients with 
initial CABG who required target-vessel revascu-
larization were treated with PCI. The risk of 
stenosis of the left main coronary artery that re-
quired target-lesion revascularization was signifi-
cantly higher for patients who received bare-metal 
stents than for those who underwent CABG (haz-
ard ratio, 5.86; 95% CI, 2.03 to 16.90).
No significant differences were noted for the 
rates of death and the composite of death, Q-wave 
myocardial infarction, or stroke between the group 
that received drug-eluting stents and the CABG 
group (Fig. 3 and Table 3). However, the hazard 
ratios for each of these end points show a non-
significant trend toward higher risk among pa-
tients with stents. Despite the markedly smaller 
hazard ratio in Wave 2 as compared with Wave 
1, CABG continued to be associated with a 
lower rate of target-vessel revascularization than 
did drug-eluting stents. Among patients with 
drug-eluting stents who underwent target-ves-
sel revascularization, 90.9% underwent repeat 
PCI and 9.1% underwent CABG. All patients with 
initial CABG who underwent target-vessel re-
vascularization were treated with PCI, not re-
peat CABG. The risk of target-lesion revascular-
ization due to stenosis of the left main coronary 
artery was higher among patients who received 
drug-eluting stents than among those who un-
derwent CABG (hazard ratio, 2.98; 95% CI, 1.15 
to 7.75).
Outcomes for the Unmatched Patients
Event-free survival in the unmatched cohort was 
consistent with the lower-risk characteristics of 
the patients who underwent PCI and the higher-
risk characteristics of the patients who underwent 
CABG (see the Supplementary Appendix). Among 
the patients not included in the overall match, 
the 3-year rates of death and the composite of 
death, Q-wave myocardial infarction, or stroke 
were significantly higher in the CABG group, 
whereas the rate of target-vessel revascularization 
was higher in the PCI group. Among unmatched 
patients in Wave 1, the risks of death and the 
composite of death, Q-wave myocardial infarc-
tion, or stroke did not differ significantly between 
the two groups. However, the risk of target-vessel 
revascularization was consistently higher among 
patients who received bare-metal stents. Among 
unmatched patients in Wave 2, CABG was asso-
ciated with higher risks of death and the com-
posite of death, Q-wave myocardial infarction, or 
stroke than was PCI with drug-eluting stents, 
whereas the risk of revascularization was higher 
among patients who received stents.
Acute Complications
Acute complications occurred in 2.7% of patients 
undergoing PCI. The details of specific acute com-
plications are provided in the Supplementary Ap-
pendix.
Table 3. Hazard Ratios for Clinical Outcomes after Stenting as Compared with after CABG among Propensity-Matched Patients.*
Outcome Overall Cohort (N = 542 pairs) Wave 1 (N = 207 pairs) Wave 2 (N = 396 pairs)
Hazard Ratio  
(95% CI) P Value
Hazard Ratio  
(95% CI) P Value
Hazard Ratio  
(95% CI) P Value
Death 1.18 (0.77–1.80) 0.45 1.04 (0.59–1.83) 0.90 1.36 (0.80–2.30) 0.26
Composite outcome of death, 
Q-wave myocardial infarc-
tion, or stroke
1.10 (0.75–1.62) 0.61 0.86 (0.50–1.49) 0.59 1.40 (0.88–2.22) 0.15
Target-vessel revascularization 4.76 (2.80–8.11) <0.001 10.70 (3.80–29.90) <0.001 5.96 (2.51–14.10) <0.001
* CABG denotes coronary-artery bypass grafting. Wave 1 shows comparisons between bare-metal stents and CABG, and Wave 2 shows com-
parisons between drug-eluting stents and CABG. Hazard ratios are for the stenting group as compared with the CABG group.
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Discussion
We compared the long-term outcomes of coro-
nary stenting and CABG in a large cohort of pa-
tients with unprotected left main coronary artery 
disease. Our observational study showed that the 
risks of death and a composite of serious outcomes 
(death, Q-wave myocardial infarction, or stroke) 
were similar in the PCI and the CABG groups. 
These results were consistent when bare-metal 
stents or drug-eluting stents were compared with 
CABG, although there was a nonsignificant trend 
toward higher risk with drug-eluting stents. In 
contrast, the rate of target-vessel revascularization 
was significantly lower in the CABG group than 
in the PCI group, although hazard ratios varied 
depending on the type of stent.
Another large observational study, published 
before the development of drug-eluting stents, sug-
gested that patients with left main coronary ar-
tery disease did significantly better with CABG 
than with PCI.20 Although this was a risk-adjusted 
analysis, patient-selection factors probably con-
tributed to the results. More recent observational 
studies have shown similar mortality rates and 
similar risks of major adverse cardiac and cerebro-
vascular events between patients receiving drug-
eluting stents and those undergoing CABG, al-
though patients undergoing CABG have typically 
had significantly lower rates of repeat revascu-
larization.15,21-23 These studies have all been lim-
ited by small numbers of patients, a limited du-
ration of follow-up, and selective performance of 
PCI in patients considered to be poor candidates 
for CABG.
In our study, despite the lower rates of repeat 
revascularization with drug-eluting stents than 
with bare-metal stents, CABG was still more ef-
fective than drug-eluting stents in reducing the 
need for target-vessel revascularization. However, 
there was a significantly higher rate of follow-up 
angiography in the PCI group than in the CABG 
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Figure 2. Kaplan–Meier Curves for Outcomes in a Cohort 
of Patients Matched for Propensity Scores Who Received 
Bare-Metal Stents or Underwent Bypass Surgery.
Propensity matching for Wave 1 created 207 matched 
pairs of patients. Panel A shows the outcomes for over-
all survival; Panel B, outcomes for freedom from death, 
Q-wave myocardial infarction, or stroke; and Panel C, 
outcomes for freedom from target-vessel revascular-
ization. Event-free survival rates (at 1, 2, and 3 years) 
were derived from paired Kaplan–Meier curves. CABG 
denotes coronary-artery bypass grafting.
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group (73.0% vs. 14.6%, P<0.001). Therefore, the 
rate of asymptomatic graft stenosis or occlusion 
may have been underestimated in the CABG group 
relative to the PCI group.
The major limitation of this study is that we 
evaluated observational data, and therefore the 
treatment strategy was not based on randomized 
assignment. The choice of revascularization was 
at the discretion of the treating physician or the 
patient. In the Supplementary Appendix we have 
attempted to provide as clear a description as 
possible of the factors that were likely to have 
influenced the selection of a procedure for indi-
vidual patients. We acknowledge, however, that 
the particulars of clinical practice in the institu-
tions in this trial, as well as the specific exper-
tise of the interventional cardiologists and cardiac 
surgeons who performed the procedures, may 
differ from those of other institutions and prac-
titioners, potentially limiting the reproducibility 
of these results in other settings.
From an analytical standpoint, our findings are 
subject to selection bias and confounding with 
respect to the relative severity of preprocedural 
risks among patients who underwent PCI and 
those who underwent CABG. To minimize these 
biases, we used propensity-score matching.16,17 
Previous research has suggested that matching 
according to the propensity score eliminates a 
greater proportion of baseline differences be-
tween two treatments than does stratification or 
covariate adjustment.24 Nevertheless, hidden bias 
may remain because of the influence of unmea-
sured confounders. Given these issues and the 
findings of our study, we believe that a random-
ized trial of PCI with drug-eluting stents as com-
pared with CABG is warranted in patients with 
Figure 3. Kaplan–Meier Curves for Outcomes in a  
Cohort of Patients Matched for Propensity Scores Who 
Received Drug-Eluting Stents or Underwent Bypass 
Surgery.
Propensity matching for Wave 2 created 396 matched 
pairs of patients. Panel A shows outcomes for overall 
survival; Panel B, outcomes for freedom from death, 
Q-wave myocardial infarction, or stroke; and Panel C, 
outcomes for freedom from target-vessel revascular-
ization. Event-free survival rates (at 1, 2, and 3 years) 
were derived from paired Kaplan–Meier curves. CABG 
denotes coronary-artery bypass grafting.
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unprotected left main coronary artery disease who 
are candidates for revascularization.
A final caveat is that our analysis was under-
powered to detect significant differences in mor-
tality, especially in the comparison of drug-elut-
ing stents with CABG. More than 5500 patients 
would have been needed for such an analysis. Non-
significant trends toward higher event rates were 
seen in the group that received drug-eluting stents; 
these trends might have been significant with a 
larger cohort of patients.
In conclusion, we found that in matched co-
horts of patients with unprotected left main 
coronary artery disease, PCI with stenting and 
CABG were associated with similar long-term 
rates of death and the composite end point of 
death, Q-wave myocardial infarction, or stroke. 
Rates of target-vessel revascularization were high-
er among patients who underwent PCI than among 
those who underwent CABG.
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